ID

23733

Description

RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00601120

Lien

https://clinicaltrials.gov/show/NCT00601120

Mots-clés

Versions (1)
  1. 12/07/2017 12/07/2017 -
Téléchargé le

12 juillet 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Renal Cell Carcinoma NCT00601120

Anglais

Eligibility Renal Cell Carcinoma NCT00601120

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients who are on antiangiogenic therapy for a minimum of 4 weeks and have isolated metastatic lesions showing either persistence or resistance to therapy that might benefit from local therapy such as rf ablation.
Description

ID.1

Type de données

boolean

Alias
UMLS CUI [1,1]
C2363719
UMLS CUI [1,2]
C0027627
male or female patients 18 years of age or older
Description

ID.2

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
clinical, radiographic, or pathologic diagnosis of clear cell rcc
Description

ID.3

Type de données

boolean

Alias
UMLS CUI [1]
C0279702
ongoing treatment with sorafenib or sunitinib, off clinical trials
Description

ID.4

Type de données

boolean

Alias
UMLS CUI [1,1]
C1516119
UMLS CUI [1,2]
C1176020
acceptable risk for general anesthesia in the judgement of the study investigator and by the department of anesthesiology upon preoperative testing.
Description

ID.5

Type de données

boolean

Alias
UMLS CUI [1,1]
C0035649
UMLS CUI [1,2]
C0002915
at least one lesion that has not completely resolved while on antiangiogenic therapy
Description

ID.6

Type de données

boolean

Alias
UMLS CUI [1,1]
C0221198
UMLS CUI [1,2]
C2699488
candidate lesions of 1cm or greater in diameter
Description

ID.7

Type de données

boolean

Alias
UMLS CUI [1,1]
C0221198
UMLS CUI [1,2]
C0456389
safe access to the tumor for a needle placed under ultrasound guidance
Description

ID.8

Type de données

boolean

Alias
UMLS CUI [1]
C2041187
ecog performance status of 0 or 1
Description

ID.9

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
adequate bone marrow, and renal as assessed by the laboratory requirements outlined in the protocol
Description

ID.10

Type de données

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0232804
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
history of bleeding diathesis or unexpected surgical bleeding
Description

ID.11

Type de données

boolean

Alias
UMLS CUI [1]
C0005779
patients currently on anticoagulation
Description

ID.12

Type de données

boolean

Alias
UMLS CUI [1]
C0003281
medical contraindication to mr imaging (pacemaker, metal debris in eye, etc.)
Description

ID.13

Type de données

boolean

Alias
UMLS CUI [1,1]
C0522473
UMLS CUI [1,2]
C0024485
prior rf to the index tumor
Description

ID.14

Type de données

boolean

pregnant or lactating
Description

ID.15

Type de données

boolean

Alias
UMLS CUI [1,1]
C0600457
UMLS CUI [1,2]
C2828358
Retour au début de la page

Similar models

Eligibility Renal Cell Carcinoma NCT00601120

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patients who are on antiangiogenic therapy for a minimum of 4 weeks and have isolated metastatic lesions showing either persistence or resistance to therapy that might benefit from local therapy such as rf ablation.
boolean
C2363719 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
ID.2
Item
male or female patients 18 years of age or older
boolean
C0001779 (UMLS CUI [1])
ID.3
Item
clinical, radiographic, or pathologic diagnosis of clear cell rcc
boolean
C0279702 (UMLS CUI [1])
ID.4
Item
ongoing treatment with sorafenib or sunitinib, off clinical trials
boolean
C1516119 (UMLS CUI [1,1])
C1176020 (UMLS CUI [1,2])
ID.5
Item
acceptable risk for general anesthesia in the judgement of the study investigator and by the department of anesthesiology upon preoperative testing.
boolean
C0035649 (UMLS CUI [1,1])
C0002915 (UMLS CUI [1,2])
ID.6
Item
at least one lesion that has not completely resolved while on antiangiogenic therapy
boolean
C0221198 (UMLS CUI [1,1])
C2699488 (UMLS CUI [1,2])
ID.7
Item
candidate lesions of 1cm or greater in diameter
boolean
C0221198 (UMLS CUI [1,1])
C0456389 (UMLS CUI [1,2])
ID.8
Item
safe access to the tumor for a needle placed under ultrasound guidance
boolean
C2041187 (UMLS CUI [1])
ID.9
Item
ecog performance status of 0 or 1
boolean
C1520224 (UMLS CUI [1])
ID.10
Item
adequate bone marrow, and renal as assessed by the laboratory requirements outlined in the protocol
boolean
C0005953 (UMLS CUI [1,1])
C0232804 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
ID.11
Item
history of bleeding diathesis or unexpected surgical bleeding
boolean
C0005779 (UMLS CUI [1])
ID.12
Item
patients currently on anticoagulation
boolean
C0003281 (UMLS CUI [1])
ID.13
Item
medical contraindication to mr imaging (pacemaker, metal debris in eye, etc.)
boolean
C0522473 (UMLS CUI [1,1])
C0024485 (UMLS CUI [1,2])
ID.14
Item
prior rf to the index tumor
boolean
ID.15
Item
pregnant or lactating
boolean
C0600457 (UMLS CUI [1,1])
C2828358 (UMLS CUI [1,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial